BAX · XBRL financial data

Baxter International financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BAX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	11,673	12,784	15,113	14,813	10,636	11,244
Cost of goods and services sold	7,086	7,679	9,716	9,838	6,652	7,865
Gross profit	4,587	5,105	5,397	4,975	3,984	3,379
Research and development	521	534	605	667	590	518
Selling, general and administrative	2,469	2,867	3,887	3,946	2,967	2,890
Other operating income (expense)	19	6	(36)	28	12	206
Operating income (loss)	1,616	1,710	(1,943)	390	14	(308)
Interest income	19	14	20	70	67	52
Interest expense	153	206	415	512	408	290
Other income (expense)	(190)	(41)	(15)	(51)	38	41
Income tax expense (benefit)	182	182	68	(34)	37	395
Net income (loss)	1,102	1,284	(2,433)	2,656	(649)	(957)
Earnings per share, basic USD per share	2.17	2.56	(4.83)	5.25	(1.27)	(1.87)
Earnings per share, diluted USD per share	2.13	2.53	(4.83)	5.25	(1.27)	(1.87)
Weighted average shares, basic millions of shares	509	502	504	506	510	513
Weighted average shares, diluted millions of shares	517	508	504	506	510	513

Fiscal years (BAX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	3,730	2,951	1,718	3,194	1,764	1,966
Accounts receivable	2,077	2,629	2,659	2,690	1,679	1,861
Inventory	1,916	2,453	2,718	2,824	2,046	2,232
Prepaid and other current assets	688	839	916	892	753	813
Total current assets	8,411	8,872	8,011	9,600	8,853	6,872
Property and equipment, net	4,722	5,178	4,979	4,433	2,870	2,910
Right-of-use asset	603	630	550	524	306	276
Goodwill	3,217	9,836	6,843	6,514	5,275	4,929
Total assets	20,019	33,521	28,287	28,276	25,782	20,055
Accounts payable	1,043	1,246	1,139	1,241	968	999
Accrued liabilities	1,884	2,479	2,202	2,594	1,861	1,968
Total current liabilities	3,333	4,236	4,745	6,503	6,511	2,970
Lease liability, non-current	501	522	456	438	243	223
Total liabilities	11,293	24,400	22,392	19,808	18,758	13,953
Retained earnings	16,328	17,065	14,050	16,114	14,929	13,705
Total stockholders' equity	8,689	9,077	5,833	8,402	6,964	6,129
Total liabilities and equity	20,019	33,521	28,287	28,276	25,782	20,055
Common shares outstanding (cover page) millions of shares	505	502	505	508	512	514

Fiscal years (BAX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,102	1,284	(2,433)	2,656	(649)	(957)
Stock-based compensation	130	146	154	133	114	117
Depreciation and amortization	823	890	1,403	1,263	997	981
Net cash from operating activities	1,868	2,222	1,211	1,726	1,019	845
Net cash from investing activities	(1,179)	(11,200)	(931)	3,213	(626)	2,841
Share repurchases	500	600	32	0	0	—
Dividends paid	473	530	573	586	590	348
Proceeds from long-term debt	1,885	11,903	0	0	0	1,998
Repayments of long-term debt	1,181	2,823	954	—	—	—
Net cash from financing activities	(345)	8,245	(1,438)	(3,489)	(1,081)	(4,216)
Net change in cash	401	(780)	(1,234)	1,476	(784)	(446)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Baxter International	1,975	2,976	558*	517.3M	Q3 FY26 10-QSep 30, 2026
West Pharmaceutical Services	464	875	190*	69.7M	Q3 FY26 10-QSep 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	Q2 FY26 10-QJun 30, 2026
Hologic	2,168	1,048	230	223.2M	Q1 FY26 10-QDec 27, 2025
Solventum	403	2,209	227*	170.2M	Q2 FY26 10-QJun 30, 2026
Medline	2,327	7,685	715*	not reported	Q2 FY26 10-QJun 27, 2026
Insulet	535	802	88*	69.4M	Q2 FY26 10-QJun 30, 2026
Align Technology	1,103	1,056	193*	71.0M	Q2 FY26 10-QJun 30, 2026
STERIS	482	1,493	367	97.5M	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.